The first experience of using {99m}Tc-Al[2]O[3]-based radiopharmaceutical for the detection of sentinel lymph nodes in cervical cancer patients

Abstract

The purpose of the study was to evaluate the feasibility of using {99m}Tc-Al[2]O[3]-based radiopharmaceutical,a novel molecular imaging agent for sentinel lymph node detection in patients with invasive cervical cancer. The study included 23 cervical cancer patients (T1aNxMx-T2bNxMx) treated at the Tomsk CancerResearch Institute. In the 18 hours before surgery, 80 MBq of the {99m}Tc-Al[2]O[3] in peritumoral injected, followed by single-photon emission computed tomography (SPECT) of the pelvis and intraoperative SLN identification. Twenty-seven SLNs were detected by SPECT, and 34 SLNs were identified by intraoperative gamma probe. The total number of identified SLNs per patient ranged from 1 to 3 (the mean number of SLNs was 1.4 per patient). The most common site for SLN detection was the external iliac region (57.2%), followed by the internal iliac (14%), obturator (14%), presacral and retrosacral regions (14%), and the parametrial region (1%). Sensitivity in detecting SLNs was 100% for intraoperative SLN identification and 79% for SPECT image.